指南与共识腹部MRCT

韩国肝癌协会-国家癌症中心指南v2022版「可能肝细胞癌」类别的诊断效能与临床意义

Diagnostic Performance and Clinical Implications of the "Probable Hepatocellular Carcinoma" Category in the Korean Liver Cancer Association-National Cancer Center Korea Guidelines v2022.
指南 / 共识 · Korean J Radiol · 2026-03-03

这项多中心回顾性研究评估了KLCA-NCC v2022指南中「可能肝细胞癌」类别的诊断效能,纳入2237例患者共2445个病灶。v2022版在MRI上联合「确定肝细胞癌」与「可能肝细胞癌」时敏感度较v2018版略高但特异度降低,单独「可能肝细胞癌」的阳性预测值低于v2018版;局灶性结节性增生或类似结节占假阳性的90.4%。

要点

  • v2022版MRI上「可能肝细胞癌」额外纳入1.5%病灶,其中104个非肝细胞癌,局灶性结节性增生或类似结节占90.4%。
  • 联合「确定」与「可能」类别时v2022版敏感度83.7%高于v2018版83.1%,特异度77.1%低于80.6%(P<0.001)。
  • v2022版单独「可能肝细胞癌」阳性预测值64.1%低于v2018版76.1%(P<0.001);无廓清动脉期高强化者阳性预测值更低。

核心结论

  • KLCA-NCC v2022版修订的「可能肝细胞癌」类别与诊断流程更新一致,在MRI和CT上表现出可接受的效能;使用MRI时局灶性结节性增生或类似结节可能被误分类为「可能肝细胞癌」。

研究设计与样本

  • 多中心回顾性研究,纳入2015年1月至2018年6月间接受钆塞酸二钠增强MRI的肝细胞癌风险患者2237例(男性1666例,平均年龄59±11岁)共2445个病灶,其中部分患者同时接受肝脏CT检查;由4名放射科医师独立判读并汇总结果,以参考标准为对照。

诊断标准与关键数值

  • v2022版MRI联合「确定肝细胞癌」与「可能肝细胞癌」的敏感度为83.7%(5670/6776)、特异度为77.1%(2316/3004);v2018版分别为83.1%(5631/6776)和80.6%(2420/3004),P<0.001。v2022版单独「可能肝细胞癌」的阳性预测值为64.1%(373/582),v2018版为76.1%(334/439),P<0.001。v2022版MRI上有非环状动脉期高强化病灶的阳性预测值为42.3%(91/215),无该征象者为76.8%(282/367),P<0.001。CT亚组(n=1590)中v2022版「可能肝细胞癌」的阳性预测值为83.8%(83/99),v2018版无病灶归入该类别。

临床应用与阅片要点

  • 判读MRI时需注意局灶性结节性增生或类似结节可能被归入「可能肝细胞癌」;非环状动脉期高强化病灶归入该类别时阳性预测值较低(42.3%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the diagnostic performance of the "probable hepatocellular carcinoma (HCC)" category in the Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 guidelines.

MATERIALS AND METHODS: This multicenter retrospective study included patients at risk of HCC who underwent gadoxetic acid-enhanced MRI between January 2015 and June 2018; a subgroup of these patients also underwent liver CT. Eligible patients had at least one non-cystic lesion (≥10 mm) with a reference standard. Four radiologists interpreted the images independently and the results were pooled. The performance of "definite HCC" and "probable HCC" together and "probable HCC" alone were compared between v2018 and v2022.

RESULTS: A total of 2,237 patients (1,666 men; mean age, 59 ± 11 years) with 2,445 lesions were included. In v2022, 1.5% (143/9,780) of the lesions were additionally categorized as "probable HCC" by four reviewers on MRI; among these, 104 lesions were not HCCs. Focal nodular hyperplasia (FNH) or FNH-like nodules constituted 90.4% (94/104) of the false positives. When "definite HCC" and "probable HCC" were combined, v2022 showed higher sensitivity (83.7% [5,670/6,776] vs. 83.1% [5,631/6,776]) but lower specificity (77.1% [2,316/3,004] vs. 80.6% [2,420/3,004]) than v2018 (P < 0.001). For "probable HCC" alone, v2022 showed a lower positive predictive value (PPV) than v2018 (64.1% [373/582] vs. 76.1% [334/439], P < 0.001). In v2022, lesions with non-rim arterial-phase hyperenhancement (APHE) showed a lower PPV than those without APHE (42.3% [91/215] vs. 76.8% [282/367], P < 0.001). In the CT subgroup (n = 1,590), 1.6% (99/6,360) of the lesions were reassessed as "probable HCC," and its PPV was 83.8% (83/99) in v2022 whereas no lesions were classified as "probable HCC" under v2018.

CONCLUSION: The revised "probable HCC" category in the KLCA-NCC v2022 aligns with updates in the diagnostic flow, demonstrating acceptable performance on MRI and CT. Notably, FNH or FNH-like nodules can be misclassified as "probable HCC" when MRI is used.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Yoon JH, Choi JY, Kim YK, et al. Diagnostic Performance and Clinical Implications of the "Probable Hepatocellular Carcinoma" Category in the Korean Liver Cancer Association-National Cancer Center Korea Guidelines v2022. Korean J Radiol. 2026. PMID: 41776851. doi:10.3348/kjr.2025.1178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。